BioStock: Ultimovacs launches fifth phase II trial with UV1

Norwegian Ultimovacs continues to expand its clinical development pipeline with universal cancer vaccine UV1. This week, the company announced its plan to initiate a fifth phase II trial with the candidate – a combination study with checkpoint inhibitor pembrolizumab in non-small cell lung cancer. The study will be conducted at 8-10 sites across Norway and led by principal investigator Professor Odd Terje Brustugun.

Read the article at biostock.se:

https://www.biostock.se/en/2021/10/ultimovacs-launches-fifth-phase-ii-trial-with-uv1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se